| SML Genetree Unveils CE-IVDR Certified NamuPlex™ Series, Accelerates Expansion into U.S. and Latin American Markets |
Molecular diagnostics company SML Genetree showcased its global market ambitions at ADLM 2025 (Association for Diagnostics & Laboratory Medicine, formerly AACC), the world’s largest clinical diagnostics conference, held in Chicago.
At the exhibition, SML Genetree introduced a range of molecular diagnostic solutions, including the NamuPlex™ GI Bacteria 2, 3 and NamuPlex™ GI Virus, which recently obtained CE-IVDR certification in Europe. These multiplex molecular diagnostic assays are designed for the rapid and precise detection of gastrointestinal infections, serving as the company’s flagship platform with enhanced global competitiveness.
In particular, SML Genetree highlighted its portfolio to CLIA-certified laboratories in the U.S., actively seeking new partnerships and collaboration opportunities. Recognized as one of the fastest-growing markets in molecular diagnostics, the U.S. represents a strategic priority for SML Genetree. Participation in ADLM 2025 provided a vital foothold for expanding its U.S. presence.
The company also held strategic meetings with key distributors and buyers across Latin America, driving discussions on product supply expansion and long-term partnerships. These efforts not only pave the way for increased sales but also strengthen SML Genetree’s position in the global diagnostics market.
Dongsoo Lee, CEO of SML Genetree, stated:
“ADLM 2025 is a crucial platform to experience the latest global diagnostic trends and explore partnership opportunities. Through our participation, we aim to showcase our technological and product strengths while achieving tangible business expansion across the U.S., Latin America, and other global markets.”
SML Genetree continues to establish itself as a leading molecular diagnostics company worldwide through ongoing innovation, advanced product development, and global certifications in the in vitro diagnostics field.
Excerpted from http://www.bosa.co.kr/news/articleView.html?idxno=2255441 | 2025.08.14
| SML Genetree Unveils CE-IVDR Certified NamuPlex™ Series, Accelerates Expansion into U.S. and Latin American Markets |
Molecular diagnostics company SML Genetree showcased its global market ambitions at ADLM 2025 (Association for Diagnostics & Laboratory Medicine, formerly AACC), the world’s largest clinical diagnostics conference, held in Chicago.
At the exhibition, SML Genetree introduced a range of molecular diagnostic solutions, including the NamuPlex™ GI Bacteria 2, 3 and NamuPlex™ GI Virus, which recently obtained CE-IVDR certification in Europe. These multiplex molecular diagnostic assays are designed for the rapid and precise detection of gastrointestinal infections, serving as the company’s flagship platform with enhanced global competitiveness.
In particular, SML Genetree highlighted its portfolio to CLIA-certified laboratories in the U.S., actively seeking new partnerships and collaboration opportunities. Recognized as one of the fastest-growing markets in molecular diagnostics, the U.S. represents a strategic priority for SML Genetree. Participation in ADLM 2025 provided a vital foothold for expanding its U.S. presence.
The company also held strategic meetings with key distributors and buyers across Latin America, driving discussions on product supply expansion and long-term partnerships. These efforts not only pave the way for increased sales but also strengthen SML Genetree’s position in the global diagnostics market.
Dongsoo Lee, CEO of SML Genetree, stated:
“ADLM 2025 is a crucial platform to experience the latest global diagnostic trends and explore partnership opportunities. Through our participation, we aim to showcase our technological and product strengths while achieving tangible business expansion across the U.S., Latin America, and other global markets.”
SML Genetree continues to establish itself as a leading molecular diagnostics company worldwide through ongoing innovation, advanced product development, and global certifications in the in vitro diagnostics field.
Excerpted from http://www.bosa.co.kr/news/articleView.html?idxno=2255441 | 2025.08.14